Repligen (RGEN) Releases FY18 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.68-0.72 for the period, compared to the Thomson Reuters consensus estimate of $0.72. The company issued revenue guidance of $180-186 million, compared to the consensus revenue estimate of $184.19 million.

Several research analysts have recently weighed in on the stock. BidaskClub cut shares of Repligen from a hold rating to a sell rating in a research report on Wednesday, February 7th. Zacks Investment Research lowered shares of Repligen from a buy rating to a hold rating in a report on Wednesday, January 24th. Citigroup initiated coverage on shares of Repligen in a report on Friday, December 8th. They issued a buy rating and a $45.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of Repligen in a report on Tuesday, December 5th. They issued an overweight rating and a $42.00 price objective on the stock. Finally, TheStreet lowered shares of Repligen from a b- rating to a c rating in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Repligen has an average rating of Buy and a consensus target price of $44.38.

Shares of Repligen (NASDAQ:RGEN) opened at $32.40 on Thursday. The stock has a market cap of $1,383.63, a PE ratio of 54.76, a P/E/G ratio of 1.78 and a beta of 0.91. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $46.81.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $41.60 million for the quarter, compared to analyst estimates of $41.13 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. Repligen’s revenue was up 62.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.08 EPS. analysts forecast that Repligen will post 0.61 EPS for the current year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the sale, the vice president now directly owns 36,554 shares in the company, valued at $1,291,818.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 8,970 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the sale, the chief executive officer now owns 83,613 shares in the company, valued at $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Repligen (RGEN) Releases FY18 Earnings Guidance” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/repligen-rgen-releases-fy18-earnings-guidance.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply